Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 372

1.

The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial.

Henriksson M, Epstein DM, Palmer SJ, Sculpher MJ, Clayton TC, Pocock SJ, Henderson RA, Buxton MJ, Fox KA.

Heart. 2008 Jun;94(6):717-23. Epub 2007 Nov 21.

PMID:
18032459
2.

Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.

Robinson M, Palmer S, Sculpher M, Philips Z, Ginnelly L, Bowens A, Golder S, Alfakih K, Bakhai A, Packham C, Cooper N, Abrams K, Eastwood A, Pearman A, Flather M, Gray D, Hall A.

Health Technol Assess. 2005 Jul;9(27):iii-iv, ix-xi, 1-158. Review.

3.

Costs of an early intervention versus a conservative strategy in acute coronary syndrome.

Epstein DM, Sculpher MJ, Clayton TC, Henderson RA, Pocock SJ, Buxton MJ, Fox KA.

Int J Cardiol. 2008 Jul 4;127(2):240-6. Epub 2007 Aug 16.

PMID:
17707103
4.

The cost-effectiveness of testing for hepatitis C in former injecting drug users.

Castelnuovo E, Thompson-Coon J, Pitt M, Cramp M, Siebert U, Price A, Stein K.

Health Technol Assess. 2006 Sep;10(32):iii-iv, ix-xii, 1-93.

5.

Economic consequences of routine coronary angiography in low- and intermediate-risk patients with unstable angina pectoris.

Desai AS, Solomon DH, Stone PH, Avorn J.

Am J Cardiol. 2003 Aug 15;92(4):363-7.

PMID:
12914862
6.

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.

Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A.

Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. Review.

7.

Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.

Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S.

Circulation. 2007 May 8;115(18):2398-409. Epub 2007 Apr 23.

8.

A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.

Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry-Smith A, Moore D.

Health Technol Assess. 2006 Jun;10(20):iii-iv, ix-113. Review.

9.

Cost-effectiveness of functional cardiac testing in the diagnosis and management of coronary artery disease: a randomised controlled trial. The CECaT trial.

Sharples L, Hughes V, Crean A, Dyer M, Buxton M, Goldsmith K, Stone D.

Health Technol Assess. 2007 Dec;11(49):iii-iv, ix-115.

10.

Is an invasive interventional strategy of value in non-ST-elevation acute coronary syndromes?

Weintraub WS.

Nat Clin Pract Cardiovasc Med. 2008 Dec;5(12):754-5. doi: 10.1038/ncpcardio1368. Epub 2008 Oct 7.

PMID:
18838964
11.

Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service?

Palmer S, Sculpher M, Philips Z, Robinson M, Ginnelly L, Bakhai A, Abrams K, Cooper N, Packham C, Alfakih K, Hall A, Gray D.

Int J Cardiol. 2005 Apr 20;100(2):229-40.

PMID:
15823630
12.

A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK.

Karnon J, Bakhai A, Brennan A, Pandor A, Flather M, Warren E, Gray D, Akehurst R.

Int J Cardiol. 2006 May 24;109(3):307-16. Epub 2005 Jul 18.

PMID:
16026869
13.

Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data.

Fox KA, Clayton TC, Damman P, Pocock SJ, de Winter RJ, Tijssen JG, Lagerqvist B, Wallentin L; FIR Collaboration.

J Am Coll Cardiol. 2010 Jun 1;55(22):2435-45. doi: 10.1016/j.jacc.2010.03.007. Epub 2010 Mar 30. Review.

14.
15.

Cost-effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial.

Briffa TG, Eckermann SD, Griffiths AD, Harris PJ, Heath MR, Freedman SB, Donaldson LT, Briffa NK, Keech AC.

Med J Aust. 2005 Nov 7;183(9):450-5.

PMID:
16274344
17.

Cost-utility analysis of physiotherapy treatment compared with physiotherapy advice in low back pain.

Rivero-Arias O, Gray A, Frost H, Lamb SE, Stewart-Brown S.

Spine (Phila Pa 1976). 2006 May 20;31(12):1381-7.

PMID:
16721304
18.

PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.

Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M; PROactive Study Group.

Diabet Med. 2007 Sep;24(9):982-1002. Epub 2007 Jun 25.

PMID:
17593245
19.

A UK trial-based cost--utility analysis of transmyocardial laser revascularization compared to continued medical therapy for treatment of refractory angina pectoris.

Campbell HE, Tait S, Buxton MJ, Sharples LD, Caine N, Schofield PM, Wallwork J.

Eur J Cardiothorac Surg. 2001 Aug;20(2):312-8.

PMID:
11463549
20.

Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial.

Kolm P, Yuan Y, Veledar E, Mehta SR, O'Brien JA, Weintraub WS.

Can J Cardiol. 2007 Nov;23(13):1037-42.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk